No Data
CICC: Maintains 3SBIO's "Outperform Industry" rating and raises the Target Price to HKD 13.50.
CICC released a Research Report stating that it maintains 3SBIO (01530)'s adjusted Net income for 2025 at 2.407 billion yuan unchanged, introducing an adjusted Net income of 2.602 billion yuan for 2026. The current stock price corresponds to an adjusted P/E of 12.7/11.5 times for 2025/2026. It maintains an outperform rating in the Industry, and due to the recent recovery of liquidity in the Hong Kong stock market and the rise in the valuation center of the Sector, the Target Price is raised by 68.8% to 13.50 Hong Kong dollars, corresponding to an adjusted P/E of 14.0/12.6 times for 2025/2026, implying a 9.9% upside. CICC's main points are as follows: The full-year performance slightly exceeded the bank's expectations for the company, which announced the performance for 2024.
SiChuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 Annual Report.
Summary of the 2024 Annual Report of SiChuan Baili Tianheng Pharmaceutical Co., Ltd.
Bailitanheng (688506.SH) released its 2024 performance, with a net income of 3.708 billion yuan, turning from a loss to a profit year-on-year.
Baillie Gifford (688506.SH) disclosed the 2024 annual report, showing revenue of 58.23...
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Express News | Sichuan Biokin Pharmaceutical Says Funds Will Be Used for Drug Research and Development
